Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended dose for phase II clinical trials (RP2D), and preliminary efficacy.
Women aged 18 to 75 (inclusive)
Subjects with histologically or cytologically confirmed recurrent or metastatic solid tumors who experience disease progression after standard treatment, or who do not have a standard treatment plan or are not suitable for standard treatment.
ECOG score is 0 or 1
An expected survival of ≥3 months
Have other malignancies within the past 5 years
Active central nervous system metastasis without surgery or radiotherapy
Presence with uncontrollable third space effusion
Have undergone other anti-tumor treatment within 4 weeks before the first dose